ES2013667A6 - Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores. - Google Patents
Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores.Info
- Publication number
- ES2013667A6 ES2013667A6 ES8901300A ES8901300A ES2013667A6 ES 2013667 A6 ES2013667 A6 ES 2013667A6 ES 8901300 A ES8901300 A ES 8901300A ES 8901300 A ES8901300 A ES 8901300A ES 2013667 A6 ES2013667 A6 ES 2013667A6
- Authority
- ES
- Spain
- Prior art keywords
- necrosis factor
- tumor necrosis
- factor formulations
- formulations
- formulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PROCEDIMIENTO PARA OBTENER UN PREPARADO FARMACEUTICO LIOFILIZADO DE FACTOR DE NECROSIS DE TUMORES. CONSISTE EN MEZCLAR, A APROXIMADAMENTE LA TEMPERATURA AMBIENTE, 1) UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE FACTOR DE NECROSIS DE TUMORES, 2) UN MATERIAL ESTABILIZADOR FISIOLOGICAMENTE ACEPTABLE SELECCIONADO ENTRE PROTEINAS, POLISACARIDOS, POLIMEROS HIDROFILOS ORGANICOS Y OLIGOSACARIDOS, 3) UN TAMPON FISIOLOGICAMENTE ACEPTABLE Y 4) UNA CANTIDAD EFICAZ DE UN SOLUTO DE CRISTALIZACION FISIOLOGICAMENTE ACEPTABLE, EMPLEANDOSE DICHO SOLUTO DE CRISTALIZACION, CUANDO EL MATERIAL ESTABILIZADOR ES UN OLIGOSACARIDO, EN UNA RELACION EN PESO CON EL OLIGOSACARIDO DE AL MENOS 2:1; FILTRAR LA MEZCLA EN CONDICIONES ESTERILES A APROXIMADAMENTE LA TEMPERATURA AMBIENTE; Y LIOFILIZAR LA MEZCLA CONGELANDOLA PRIMERO Y SECANDOLA SEGUIDAMENTE A UNA TEMPERATURA INFERIOR A 0GC. LOS PREPARADOS OBTENIDOS SON UTILES COMO AGENTES INMUNOLOGICOS ADMINISTRABLES POR VIA PARENTERAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/181,077 US5215743A (en) | 1988-04-13 | 1988-04-13 | Tumor necrosis factor formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2013667A6 true ES2013667A6 (es) | 1990-05-16 |
Family
ID=22662812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES8901300A Expired - Fee Related ES2013667A6 (es) | 1988-04-13 | 1989-04-13 | Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores. |
Country Status (8)
Country | Link |
---|---|
US (1) | US5215743A (es) |
EP (1) | EP0423244B1 (es) |
JP (1) | JPH03504721A (es) |
AU (1) | AU3447389A (es) |
DE (1) | DE68913537D1 (es) |
ES (1) | ES2013667A6 (es) |
IL (1) | IL89930A0 (es) |
WO (1) | WO1989009610A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002531A1 (en) * | 1989-08-17 | 1991-03-07 | Peter Maccallum Cancer Institute | Method for the modulation of haemopoiesis in a mammal |
AU2309692A (en) * | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
FR2684878B1 (fr) * | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
US20020031563A1 (en) * | 1992-09-30 | 2002-03-14 | Hodge Thomas W. | Method of inhibiting tumor necrosis factor |
JPH0776527A (ja) * | 1993-06-28 | 1995-03-20 | Hayashibara Biochem Lab Inc | 半固形製剤とその製造方法 |
US6270757B1 (en) * | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
RU2065307C1 (ru) * | 1994-12-13 | 1996-08-20 | Александр Васильевич Тихонов | Способ лечения первичного рака печени и набор для лечения первичного рака печени |
AU695129B2 (en) * | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
US6126933A (en) * | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
AUPO066096A0 (en) * | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
WO1999018119A1 (fr) * | 1997-10-03 | 1999-04-15 | Shionogi & Co., Ltd. | Procede de lyophilisation de proteines |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US20030187196A1 (en) * | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
ES2332402T5 (es) * | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
KR20050042032A (ko) * | 2001-11-02 | 2005-05-04 | 세키스이가가쿠 고교가부시키가이샤 | 사이토카인 유도 재료 및 사이토카인 유도 용구 |
US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
WO2004045376A2 (en) * | 2002-11-15 | 2004-06-03 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
ES2347239T3 (es) * | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
SI2335725T1 (sl) * | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
EP2266600B1 (en) | 2004-07-26 | 2014-09-10 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
JP2010519220A (ja) * | 2007-02-16 | 2010-06-03 | ワイス エルエルシー | マンニトール誘導性のタンパク質凝集を抑制するためのスクロースの使用 |
SG174258A1 (en) * | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
US11365229B2 (en) | 2012-09-10 | 2022-06-21 | Xencor, Inc. | Methods of treating neurological diseases |
WO2014064637A1 (en) | 2012-10-26 | 2014-05-01 | Lupin Limited | Stable pharmaceutical composition of tnfr:fc fusion protein |
WO2014124134A1 (en) | 2013-02-07 | 2014-08-14 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
CN104274827B (zh) * | 2013-07-01 | 2020-07-14 | 上海贺普药业股份有限公司 | 贺普拉肽的制剂 |
TWI593967B (zh) * | 2014-05-01 | 2017-08-01 | 高雄醫學大學 | 二級抗體所辨識之抗原決定位及其用途 |
ES2962885T3 (es) | 2015-05-15 | 2024-03-21 | Massachusetts Gen Hospital | Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral |
US10519207B2 (en) | 2015-06-12 | 2019-12-31 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating opioid tolerance |
WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
WO2017197331A2 (en) | 2016-05-13 | 2017-11-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
CN106729633A (zh) * | 2017-03-03 | 2017-05-31 | 上海唯科生物制药有限公司 | 一种肿瘤坏死因子直肠给药制剂及其制备方法 |
CN106620656A (zh) * | 2017-03-03 | 2017-05-10 | 上海唯科生物制药有限公司 | 一种肿瘤坏死因子舌下给药制剂及其制备方法 |
CN111110638B (zh) * | 2020-01-10 | 2022-10-14 | 广州市丹蓝生物科技有限公司 | 一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447355A (en) * | 1982-04-07 | 1984-05-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same |
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
US4797388A (en) * | 1984-05-21 | 1989-01-10 | Cetus Corporation | Pharmaceutical compositions with galactitol as carrier |
JPS60258125A (ja) * | 1984-06-06 | 1985-12-20 | Hayashibara Biochem Lab Inc | 蛋白性生理活性物質を含有する水溶性乾燥物 |
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
US4677063A (en) * | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
JPH0710342B2 (ja) * | 1985-12-26 | 1995-02-08 | 株式会社林原生物化学研究所 | 無水アルドヘキソ−スによる含水物の脱水方法 |
US4762857A (en) * | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
-
1988
- 1988-04-13 US US07/181,077 patent/US5215743A/en not_active Expired - Fee Related
-
1989
- 1989-03-22 DE DE89909946T patent/DE68913537D1/de not_active Expired - Lifetime
- 1989-03-22 AU AU34473/89A patent/AU3447389A/en not_active Abandoned
- 1989-03-22 WO PCT/US1989/001226 patent/WO1989009610A1/en active IP Right Grant
- 1989-03-22 EP EP89909946A patent/EP0423244B1/en not_active Expired - Lifetime
- 1989-03-22 JP JP1504712A patent/JPH03504721A/ja active Pending
- 1989-04-12 IL IL89930A patent/IL89930A0/xx unknown
- 1989-04-13 ES ES8901300A patent/ES2013667A6/es not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH03504721A (ja) | 1991-10-17 |
WO1989009610A1 (en) | 1989-10-19 |
AU3447389A (en) | 1989-11-03 |
EP0423244A1 (en) | 1991-04-24 |
EP0423244B1 (en) | 1994-03-02 |
IL89930A0 (en) | 1989-12-15 |
US5215743A (en) | 1993-06-01 |
DE68913537D1 (de) | 1994-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2013667A6 (es) | Procedimiento para obtener un preparado farmaceutico liofilizado de factor de necrosis de tumores. | |
BG108927A (en) | INBIEBLES OF INTERLEVKIN - 1BETA - CONVERTING ENZYME, METHOD OF RECEIVING THEM, PHARMACEUTICAL COMPOSITION THAT CONTAINS AND USING THEM AS MEDICINAL | |
EG18334A (en) | Pyrozoline compounds and their use as pesticides | |
IL74497A0 (en) | Pharmaceutical compositions and phenyl carbamate derivatives | |
NZ225491A (en) | Benzamide derivatives, their preparation and plant growth regulating compositions | |
IL77396A (en) | Pharmaceutical compositions containing bicyclic heteroarylpiperazine derivatives,certain such novel compounds and their preparation | |
NZ240230A (en) | Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof | |
IL75197A0 (en) | Aminotetralin derivatives,their preparation and pharmaceutical compositions containing them | |
IL94433A0 (en) | Aminophenol derivatives,their preparation and pharmaceutical compositions containing them | |
GR3007385T3 (es) | ||
ES8107192A1 (es) | Un procedimiento para la preparacion de un compuesto sele- ccionado entre el grupo formado por una imidazolilurea | |
DE3572977D1 (en) | Indole derivatives, their preparation, their use as medicines and compositions containing them | |
FI853648A0 (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva 4,5-dihydro-4-okso-2-/(2-trans-fenylcyklopropyl) amino/-3-furankarboxylsyror och derivat daerav. | |
IL85189A (en) | Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them | |
IL111966A0 (en) | 4-Benzoylisoxazole derivatives, their preparation and herbicidal compositions containing them | |
ES8405054A1 (es) | Procedimiento para la obtencion de granulados dispersables o bien solubles en agua. | |
ES8608516A1 (es) | Procedimiento para la preparacion de acidos 4-isoxazolil- tiazol-2-oxamicos y sus derivados | |
ATE13184T1 (de) | Aldehydaddukte des triamterens und sie enthaltende pharmazeutische zusammensetzungen. | |
IL82143A (en) | Pharmaceutical compositions containing interleukin-2 and tumor necrosis factor | |
ZA891783B (en) | Peptides with pharmaceutical activity | |
IL76452A0 (en) | Vinylphenyl substituted tetrazol derivatives,their preparation and pharmaceutical compositions containing them | |
ES8706138A1 (es) | Procedimiento para la obtencion de nuevas benzoilureas | |
ES465578A1 (es) | Procedimiento para la obtencion de preparados farmaceuticos diureticos, antihipertensivos y cardiales | |
IL64319A (en) | Plant growth regulating compositions containing bicyclo(2.2.1)heptane-2-oxime derivatives,certain such novel compounds and their preparation | |
ES2000182A6 (es) | Procedimiento para la obtencion de (iso) ureas substituidas potenciadoras del rendimiento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1A | Transfer granted |
Owner name: CETUS ONCOLOGY CORPORATION |
|
PC1A | Transfer granted | ||
FD1A | Patent lapsed |
Effective date: 20041102 |